NCT01536743 2020-06-05A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionJonsson Comprehensive Cancer CenterPhase 2 Completed26 enrolled